RNASE1 and gastric cancer: Notably, by analyzing public datasets derived from gastric cancer (n = 45, ERP107734, anti-PD-1 treatment) and renal cell carcinoma (RCC) datasets (n = 29, SRP128156, anti-PD-1/anti-PD-1+anti-CTLA4 treatment) through “Immune Checkpoint Blockade Therapy Atlas (ICBatlas, URL: http://bioinfo.life.hust.edu.cn/ICBatlas/#!/), we found that non-responders displayed significantly higher expression of RNase1 than responders in gastric cancer and RCC datasets (P = 0.045 and P = 0.010) (Supplementary Table 8).